Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting

New data on multiple Bristol-Myers Squibb Company compounds will be presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 29 to November 2.

3 Oct 2010

Stem cell research breakthrough

Australian researchers have grown new human stem cells outside the body and this may provide new hope to cancer patients and those with genetic disorders. The team found a way to manipulate the environment of blood-forming stem cells to make them multiply.

3 Oct 2010

Encorium announces extension of expiration date for pending rights offering

Encorium Group, Inc. , a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it has extended the expiration date for its pending rights offering from September 30, 2010 to October 15, 2010. The subscription rights may now be exercised at any time prior to 5:00 p.m. ET on Friday, October 15, 2010.

1 Oct 2010

Elekta releases Atlas-based Autosegmentation 2.0 software for increasing contouring accuracy

Elekta recently launched ABAS (Atlas-based Autosegmentation) 2.0 software, which includes the Simultaneous Truth and Performance Level Estimation (STAPLE) algorithm to increase contouring accuracy. ABAS—considered the industry gold standard for autosegmentation accuracy—deforms atlases of anatomy previously defined on a reference image onto a new patient image, creating a new structure set fit to the patient anatomy and enhancing planning efficiency.

From Elekta 1 Oct 2010

Benicar better than Cozaar in reducing blood pressure: Study

New study results show that patients treated with Benicar® (olmesartan medoxomil) 40 mg once daily had significantly greater reductions in blood pressure and higher rates of goal attainment than patients receiving Cozaar® (losartan potassium) 100 mg once daily at week 8, according to findings of a new head-to-head study presented today at the late breaker session at the 23rd Scientific Meeting of the International Society of Hypertension (ISH) in Vancouver, Canada.

1 Oct 2010

GSA urges treatment of sepsis as a medical emergency

The Global Sepsis Alliance (GSA) is urging healthcare providers, patients and policymakers worldwide to treat sepsis as a medical emergency. "Tens of millions of people die from sepsis each year, making it the likely leading cause of death worldwide. Sepsis kills regardless of age, ethnicity, location and access to care," said Konrad Reinhart, M.D., Chairman of the GSA and director of the Department of Anesthesiology and Intensive Care Medicine, University Hospital of the Friedrich Schiller, University of Jena, Germany.

1 Oct 2010

Center for Excellence in Sickle Cell Disease established by Vanderbilt and Meharry

A Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease has been established by Vanderbilt University Medical Center and Meharry Medical College. The Center will seek to bring high quality care to people with sickle cell disease (SCD) that is seamless and lifelong.

1 Oct 2010

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.

1 Oct 2010

DMC recommends continuation of enrollment in Celsion's Phase III ThermoDox HEAT study for primary liver cancer

Celsion Corporation, a leading oncology drug development company, announced that after reviewing data from 401 patients enrolled in its pivotal Phase III ThermoDox ® clinical study (the HEAT study) for primary liver cancer, the Data Monitoring Committee (DMC) has unanimously recommended that the trial continue to enroll patients with the goal of reaching the 600 patients required to complete the study.

1 Oct 2010

Study finds benefits of mammograms for women in their 40s, sparking disagreement

The New York Times: "Researchers reported Wednesday that mammograms can cut the breast cancer death rate by 26 percent for women in their 40s. But their results were greeted with skepticism by some experts who say they may have overestimated the benefit.

1 Oct 2010

Neurologic Clinics journal publishes latest advances in neurologic disorders

The latest advances in treating neurologic disorders such as stroke, headache, Parkinson's disease, epilepsy and sleep disorders are detailed in a special issue of the journal Neurologic Clinics.

1 Oct 2010

Breast cancer breakthrough

New research on gene expression provides a breakthrough in breast cancer treatment. Women who have triple-negative breast cancer are a small proportion of breast cancer cases, but it is difficult to treat and might have a more aggressive clinical course than other forms of the disease.

30 Sep 2010

Consumption of caffeinated coffee and alcohol reduces risk of contracting late onset diabetes

In a very large cohort of African-American women in the US, the association between the consumption of alcohol, tea, and coffee and the development of type 2 diabetes mellitus (late onset diabetes) was studied for 12 years. Tea and decaffeinated coffee showed no relation with diabetes, but the regular moderate intake of both caffeinated coffee and alcohol appeared to reduce the risk of contracting late onset diabetes significantly.

30 Sep 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.

30 Sep 2010

Warburg Pincus to invest CDN $35 million in Protox

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, today jointly announced that they have entered into an Investment Agreement.

30 Sep 2010

Multi-disciplinary approach increases breast cancer survival rate: Study

Advances in screening for disease detection, better surgical techniques available to more women, and an increased number of therapies that reduce the risk of relapse in patients with both locally advanced and early stage disease, have collectively contributed to dramatic improvements in breast cancer's survival rates, according to a review of 60 years of patient records at The University of Texas MD Anderson Cancer Center.

30 Sep 2010

Canadian Cancer Society alarmed by government inaction to establish national catastrophic drug insurance program

A large majority of Canadians - 85 per cent - say if they were diagnosed with cancer the cost of drugs would have a negative impact on their personal finances, according to poll results released today by the Canadian Cancer Society.

30 Sep 2010

Study shows immunotherapy improves survival rate in children with neuroblastoma

Using immunotherapy biologic agents that stimulate the body's immune system pediatric oncologists have achieved the first substantial increase in over a decade in cure rates for the childhood cancer neuroblastoma. A newly released study shows that the new treatment improved two-year survival rates by 20 percent, compared to standard treatment for an aggressive form of neuroblastoma, a cancer of the nervous system.

30 Sep 2010

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

Patients with triple negative breast cancer that also have mutations in the BRCA gene appear to have a lower risk of recurrence, compared to those with the same disease without the deleterious genetic mutation, according to researchers at The University of Texas MD Anderson Cancer Center.

30 Sep 2010

Oncology News and Research

Further Reading

Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting

Stem cell research breakthrough

Encorium announces extension of expiration date for pending rights offering

Elekta releases Atlas-based Autosegmentation 2.0 software for increasing contouring accuracy

Benicar better than Cozaar in reducing blood pressure: Study

GSA urges treatment of sepsis as a medical emergency

Center for Excellence in Sickle Cell Disease established by Vanderbilt and Meharry

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

DMC recommends continuation of enrollment in Celsion's Phase III ThermoDox HEAT study for primary liver cancer

Study finds benefits of mammograms for women in their 40s, sparking disagreement

Neurologic Clinics journal publishes latest advances in neurologic disorders

Breast cancer breakthrough

Consumption of caffeinated coffee and alcohol reduces risk of contracting late onset diabetes

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

Warburg Pincus to invest CDN $35 million in Protox

Multi-disciplinary approach increases breast cancer survival rate: Study

Canadian Cancer Society alarmed by government inaction to establish national catastrophic drug insurance program

Study shows immunotherapy improves survival rate in children with neuroblastoma

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News